




RealRate

PHARMACEUTICAL 2023

Korro Bio Inc
Rank 284 of 471

FREQUENCY
THERAPEUTICS



The relative strengths and weaknesses of Korro Bio Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Korro Bio Inc compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 37% points. The greatest weakness of Korro Bio Inc is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 44% points.

The company's Economic Capital Ratio, given in the ranking table, is 214%, being 31% points below the market average of 245%.

Input Variable	Value in 1000 USD
Assets, Current	87,493
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	21,026
Liabilities, Non-Current	26,850
Other Assets	31,006
Other Compr. Net Income	-136
Other Expenses	959
Other Liabilities	4,167
Other Net Income	2,381
Other Revenues	0
Property and Equipment	2,739
Research and Development	49,418
Selling, General and Administrative Expense	33,584

Output Variable	Value in 1000 USD
Assets	121,238
Liabilities	52,043
Expenses	83,961
Revenues	0
Stockholders Equity	69,195
Net Income	-81,580
Comprehensive Net Income	-81,648
BaseVar	129,880
ECR before LimitedLiability	80%
Economic Capital Ratio	214%